A Game-Changing Step in Cancer Treatment: Personalized Vaccines Are Coming

The hopeful news we have been waiting for a long time from the medical world has finally arrived. Research in cancer treatment, which has been going on for years, is entering a brand new and very powerful era with personalized mRNA vaccines. Moreover, scientific excitement in this field is not limited to global laboratories; Research centers in Portugal are at the heart of this great transformation.

Pharmaceutical giants Moderna and Merck announced that they achieved critical targets in the comprehensive Phase 3 study in which the experimental mRNA vaccine intimmeran autogene they developed and the immunotherapy drug Keytruda were used together.

This study, conducted with 1,137 advanced-stage melanoma (skin cancer) patients whose tumors were surgically removed, showed that the vaccine significantly prevented the disease from recurring and spreading to other parts of the body. The fact that a personalized mRNA cancer vaccine has achieved such concrete success in Phase 3 is a first in the history of medicine.

Not a Flu Vaccine, but a Cellular Defense Guide

This vaccine should not be confused with the flu or Covid vaccines we are used to. The goal is not to prevent getting sick; fighting cancer that already exists in the body.

The process is completely personalized:

Tumor tissue taken from the patient is genetically examined and mutations specific to that cancer are detected.

A special mRNA formula is produced that directly introduces these targets to the patient's immune system.

The body learns to precisely target and destroy cancerous cells with its own defense mechanism.

This promising process, which started with melanoma; It is expected to open the door to cancer types that are much more difficult to treat, such as lung, kidney, bladder and pancreas.

What Are Scientists Doing in Lisbon?

The Portuguese leg of this global breakthrough is also quite remarkable. The Champalimaud Foundation, located in Lisbon, has been conducting worldwide studies on activating the immune system against cancer for many years.

The team, which has unraveled the mechanism of the methods used to stimulate immunity, especially in early-stage bladder cancer, has significant experience in the field of personalized medicine. Botton-Champalimaud Pancreatic Cancer Center, affiliated with the center, continues its personalized vaccine and immunotherapy studies against pancreatic cancer, one of the most difficult types to treat, without slowing down.

A New Era in Medicine: "There is No Disease, There is a Patient"

In traditional oncology, treatment was determined according to where the tumor originated in the body (such as lung, breast, stomach). Now the medical world focuses on the patient's own genetic and molecular structure rather than the location of the tumor. Personalized vaccines are exactly the realization of this understanding.

Of course, there are steps to be overcome, such as the official approval processes of the vaccine and production difficulties. But Phase 3 results clearly show that personalized immunotherapy will move from an experimental idea to a life-saving mainstream treatment.

Source: Portugal Resident